Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis

Autor:	Mark Kowalski, Jason Gotlib, Andrew W. Roberts, Linda M Bavisotto, Geeta George, Animesh Pardanani, Mark R. Litzow, G. Smith, Terra L. Lasho, Kebede H. Begna, Shireen Sirhan, William J. Hogan, Domenica Caramazza, R. F. McClure, A Tefferi, Curtis A. Hanson, Vikas Gupta
Rok vydání:	2011
Předmět:	Oncology Cancer Research medicine.medical_specialty Pediatrics Janus kinase 1 business.industry Internal medicine Interim Medicine business Myelofibrosis medicine.disease
Zdroj:	Journal of Clinical Oncology. 29:6514-6514
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2011.29.15_suppl.6514
Popis:	6514 Background: CYT387 is a potent JAK-1/2 inhibitor. In an ongoing phase-1/2 multi-center study, 108 patients with myelofibrosis (MF) have so far been accrued. We present updated interim results ...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::82a9e17bb9b5820816c8c29316861345 https://doi.org/10.1200/jco.2011.29.15_suppl.6514 Zobrazit plný text záznamu